Physician profile
Robert Stevenson
NPI 1740376805
$9,301.93
in general payments reported to CMS, 2019-2025
47 companies · $1,688 in 2025
The $1,688 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,406 · 2020: $323 · 2021: $465 · 2022: $1,878 · 2023: $1,440 · 2024: $2,102 · 2025: $1,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,229 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,228.97 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,676.03 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,311.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,239.00 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Lilly USA, LLC | $797.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $458.55 | 2019-2025 | |
| Glaxosmithkline, LLC. | $437.50 | 2019-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.19 | 2019-2025 | Jardiance, Ofev |
| E.R. Squibb & Sons, L.L.C. | $307.87 | 2022-2024 | Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $292.08 | 2022-2025 | Caplyta |
| Alnylam Pharmaceuticals INC. | $228.62 | 2023-2024 | Amvuttra, Onpattro |
| Allergan, INC. | $192.54 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $189.47 | 2022-2024 | |
| Astellas Pharma US INC | $173.25 | 2019-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $170.70 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $132.49 | 2019-2021 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $94.34 | 2025 | Rexulti |
| Corium, LLC | $92.79 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $90.57 | 2023-2025 | Auvelity, Sunosi |
| Exact Sciences Corporation | $88.90 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $87.73 | 2019-2022 | |
| Amarin Pharma, INC. | $82.57 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.75 | 2019-2025 | Glassia |
| Otsuka America Pharmaceutical, INC. | $71.13 | 2023-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $66.56 | 2023-2024 | |
| Amgen INC. | $64.37 | 2022-2024 | Tezspire, Prolia, Evenity |
| Biohaven Pharmaceutical Holding Company LTD. | $50.53 | 2022 | |
| Jazz Pharmaceuticals INC. | $47.79 | 2022-2023 | Xywav |
| Axonics, INC. | $42.79 | 2020-2022 | |
| Abbott Laboratories | $35.61 | 2024-2025 | Freestyle Libre 3 |
| Biogen, INC. | $35.10 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $29.69 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Medtronic, INC. | $28.83 | 2022-2023 | Intellis Adaptivestim |
| Covis Pharma Gmbh | $28.17 | 2022 | |
| Sanofi-Aventis U.S. LLC | $25.81 | 2019 | |
| Sanofi Pasteur INC. | $25.49 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $22.01 | 2023-2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $19.78 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.70 | 2022 | |
| Mylan Specialty L.P. | $16.60 | 2019 | |
| Vanda Pharmaceuticals INC. | $16.49 | 2025 | Fanapt |
| Alexion Pharmaceuticals, INC. | $15.44 | 2022 | |
| Antares Pharma, INC. | $14.55 | 2022 | |
| Inspire Medical Systems, INC. | $14.49 | 2025 | Inspire |
| Viatris Specialty LLC | $13.63 | 2025 | Yupelri |
| Boston Scientific Corporation | $13.53 | 2025 | Wavewriter Alpha Prime 16 |
| Echosens North America, INC. | $13.04 | 2025 | Fibroscan |
| Seqirus USA INC | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stevenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.